drugset / Trial / NCT06727721
Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
RandomizedParallel-groupTriple-blindTreatment
Summary
Umbilical cord mesenchymal stem cell injection expressing OCN19, while playing the role of MSCs, can directly stimulate the expression of insulin gene and the division and proliferation of islet beta cells, which is expected to further enhance the therapeutic effect of stem cells. In non-clinical studies, it was found that MSCs expressing OCN19 had better hypoglycemic effect than MSCs
Timeline
- Start
- 2023-11-06
- Primary completion
- 2028-12-12
- Completion
- 2029-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells | Cell therapy | — | — |
| Comparator | mesenchymal stem cells | Cell therapy | — | — |